Volume 12 | Issue 9 |

 Abstract

The healthcare environment in India has evolved into a World-Class, Cost Effective Healthcare destination for Medical Tourism influenced by ancient traditions and modern advancements; India is rich in alternative therapies that are the traditions of India and time tested in Centuries still have their force to reckon in Healthcare in which the West has no answer in certain diseases/ailments. In this regard, the ancient healthcare traditions namely in Ayurveda, Yoga, Naturopathy, Siddha that have treatments and procedures of their own for certain ailments where the West has no answer in allopathy is gaining importance with establishment of Ayush. To give high standards that are equivalent to JCI India has introduced NABH to give and recognize in healthcare, the National Board of Accreditation of hospitals and healthcare services (NABH) established by the Government of India has designed guidelines for accreditation of wellness centres in collaboration with Ayush. This transformation is underscored by the commitment of the Indian Government to enhance healthcare accessibility and quality, particularly in Post Covid-19 Pandemic.

Licence: creative commons attribution 4.0

  License

Creative Commons Attribution 4.0 and The Open Definition

 Keywords

HEALTHCARE ENVIRONMENT MADE INDIA AS WORLD CLASS COST EFFECTIVE HEALTHCARE GLOBAL DESTINATION

  License

Creative Commons Attribution 4.0 and The Open Definition

 Abstract

ABSTRACT Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels. This study aimed to investigate the potential antidiabetic effects of Momordica charantia (bitter melon) and Spondias mombin (yellow mombin) on streptozotocin (STZ)-induced diabetic rats. The experiment involved six groups of rats: a normal control group, a diabetic control group, a group treated with Metformin as standard drug,a group treated with Momordica charantia, and a group treated with Spondias mombin and a group treated with combination of both herbal drug Spondias mombin and Momordica charantia . Diabetes was induced in the rats using a single intraperitoneal injection of STZ. The treatment groups received oral doses of the respective plant extracts for a duration of four weeks. The results demonstrated that both Momordica charantia and Spondias mombin exhibited significant antidiabetic effects in the diabetic rats. Treatment with these plant extracts resulted in a reduction in fasting blood glucose levels, compared to the diabetic control group. Furthermore, the plant extract-treated groups showed improved glucose tolerance and increased insulin sensitivity compared to the diabetic control group. Biochemical analysis revealed that the plant extracts effectively restored altered lipid profile parameters, including total cholesterol, triglycerides, and low-density lipoprotein cholesterol, towards normal levels. Moreover, treatment with Momordica charantia and Spondias mombin significantly attenuated oxidative stress by increasing antioxidant enzyme activity and reducing malondialdehyde levels. Histopathological examination of pancreatic tissues showed that both plant extracts preserved pancreatic architecture and reduced STZ-induced damage, such as beta-cell degeneration and inflammatory cell infiltration. In conclusion, the findings of this study indicate that Momordica charantia and Spondias mombin have potential antidiabetic properties and may provide beneficial effects in managing diabetes. These plant extracts exhibited hypoglycemic, hypolipidemic, antioxidant, and pancreatic protective effects in STZ-induced diabetic rats. Further research is warranted to explore the underlying mechanisms and identify active compounds responsible for these effects, which could lead to the development of novel therapeutic interventions for diabetes management.

Licence: creative commons attribution 4.0

  License

Creative Commons Attribution 4.0 and The Open Definition

 Keywords

Keywords: Momordica charantia, Spondias mombin, Streptozotocin, Diabetic Mellitus, T1DM, T2DM.

  License

Creative Commons Attribution 4.0 and The Open Definition